P130010/S005: VEGA Steroid-Eluting Endocardial Leads (VEGA R45, VEGA R52, and VEGA R58)
FDA’s recorded scope: manufacturing process improvements for welding of pacing leads
Explore this company’s associated devices, FDA decisions and regulatory history.

MedtechLedger currently links 8 FDA records to the applicant name MicroPort CRM S.r.l.. 7 entries are PMA supplements. 1 entry is a 30-day notice. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from Jul 23, 2025 to Jan 15, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
Product code NVN appears in 3 of the 8 linked filings. The collection spans 4 FDA product codes and 4 original PMA application families. These figures describe the filings available here; they do not establish the company’s total device sales or market share.
The largest PMA family in this collection is P130010, with 3 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes.
Applicant mailing address recorded by FDA: Via Crescentino S.N., Saluggia, 13040. Recorded on P130010/S005, decision dated Jan 15, 2026.
Drug Eluting Permanent Right Ventricular (Rv) Or Right Atrial (Ra) Pacemaker Electrodes; Defibrillator, Automatic Implantable Cardioverter, With Cardiac Resynchronization (Crt-D); Defibrillator, Implantable, Dual-Chamber; Implantable Pacemaker Pulse-Generator.
FDA’s recorded scope: manufacturing process improvements for welding of pacing leads
FDA’s recorded scope: approval for the ENERGYA/TALENTIA family of ICDs and CRT-Ds and associated SmartTouch Programmer software modules, and updates to the Remote Monitoring System.
FDA’s recorded scope: approval for the ENERGYA/TALENTIA family of ICDs and CRT-Ds and associated SmartTouch Programmer software modules, and updates to the Remote Monitoring System.
FDA’s recorded scope: approval for the ENERGYA/TALENTIA family of ICDs and CRT-Ds and associated SmartTouch Programmer software modules, and updates to the Remote Monitoring System.
FDA’s recorded scope: Approval for the addition of Mylar spacers to our ALIZEA/CELEA pacemakers, allow hybrid tab replacements to occur at Microports Saluggia, Italy facility, and changes in manufacturing processes of other MicroPorts pacemaker, ICD, and CRT-D systems.
Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| MicroPort CRM S.r.l. | PMA supplement | Jan 15, 2026 | FDA | |
| MicroPort CRM S.r.l. | PMA supplement | Nov 25, 2025 | FDA | |
| MicroPort CRM S.r.l. | PMA supplement | Nov 25, 2025 | FDA | |
| MicroPort CRM S.r.l. | PMA supplement | Nov 25, 2025 | FDA | |
| MicroPort CRM S.r.l. | PMA supplement | Jul 23, 2025 | FDA | |
| MicroPort CRM S.r.l. | PMA supplement | Jul 23, 2025 | FDA | |
| MicroPort CRM S.r.l. | PMA supplement | Jul 23, 2025 | FDA | |
| MicroPort CRM S.r.l. | PMA supplement | Jul 23, 2025 | FDA |
Source updated Nov 9, 2026. Retrieved Nov 21, 2026.